Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03012581
Previous Study | Return to List | Next Study

Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types (AcSé)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03012581
Recruitment Status : Recruiting
First Posted : January 6, 2017
Last Update Posted : November 1, 2019
Sponsor:
Collaborators:
National Cancer Institute, France
Ligue contre le cancer, France
Bristol-Myers Squibb
Information provided by (Responsible Party):
UNICANCER

Tracking Information
First Submitted Date  ICMJE January 2, 2017
First Posted Date  ICMJE January 6, 2017
Last Update Posted Date November 1, 2019
Actual Study Start Date  ICMJE June 16, 2017
Estimated Primary Completion Date January 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 4, 2017)
Objective response rate [ Time Frame: measured at the first scheduled disease assessment following study treatment initiation (Day 84, ± 7 days) ]
ORR will be assessed per cohort by an IRC according to RECIST v1.1.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 4, 2017)
  • Progression-free survival [ Time Frame: From date of inclusion until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 36 months ]
    Assessed according to RECIST v1.1
  • Overall survival [ Time Frame: From date of inclusion until the date of death from any cause, assessed up to 36 months ]
  • Best response [ Time Frame: From inclusion up to 36 months ]
    Assessed according to RECIST v1.1
  • Response duration [ Time Frame: from first observation of objective response until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 36 months ]
    Assessed according to RECIST v1.1
  • Time to response [ Time Frame: from inclusion first observation of objective response, assessed up to 36 months ]
    Assessed according to RECIST v1.1
  • Frequency and severity of adverse events [ Time Frame: from inclusion until 100 days after last dose of investigational product ]
    assessed according to the NCI-CTCAE v4
  • Objective response rate in subgroups of subjects with high versus low expression (cutoff set at the median for the population measured) of different immune markers (PD-L1, CD4+, FOXP3+, Fas-L, OX40, VEGF, CD31; CD34) [ Time Frame: measured at the first scheduled disease assessment following study treatment initiation (Day 84, ± 7 days) ]
    ORR will be assessed per cohort by an IRC according to RECIST v1.1.
  • Progression-free survival in subgroups of subjects with high versus low expression (cutoff set at the median for the population measured) of different immune markers (PD-L1, CD4+, FOXP3+, Fas-L, OX40, VEGF, CD31; CD34) [ Time Frame: From date of inclusion until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 36 months ]
    Assessed according to RECIST v1.1.
  • Overall survival in subgroups of subjects with high versus low expression (cutoff set at the median for the population measured) of different immune markers (PD-L1, CD4+, FOXP3+, Fas-L, OX40, VEGF, CD31; CD34) [ Time Frame: From date of inclusion until the date of death from any cause, assessed up to 36 months ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
Official Title  ICMJE Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
Brief Summary This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of nivolumab monotherapy in 6 cohorts of patients with specific rare cancers who have unresectable locally advanced or metastatic disease, which is resistant or refractory to standard therapy, or for which standard therapy does not exist, or is not considered appropriate, and for which no other experimental treatment options are available.
Detailed Description

The study plans to enrol up to 250 patients in total with between 20 and 50 patients assigned to each cohort according to indication, as follows:

  • Cohort 1: Non-clear cell RCC
  • Cohort 2: Rare head and neck cancer
  • Cohort 3: Rare skin cancer
  • Cohort 4: non-colorectal cancers with microsatellite instability (MSI-nonCRC)
  • Cohort 5: Penile cancer
  • Cohort 6: POLE exonucleasic domain mutated cancer

The study will use a two-stage Bayesian enrichment design. The first stage treats all patients from the different cohorts with the investigational product and identifies possibly sensitive indications. The second stage will compare outcomes among subsets of patients in the identified cohorts to distinguish between subpopulations of patients who may benefit from the treatment and patients for whom there is no evidence of efficacy.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Carcinoma, Renal Cell
  • Head and Neck Neoplasm
  • Skin Neoplasms
  • Microsatellite Instability
  • Penile Neoplasms
  • Cancer With POLE Exonucleasic Domain Mutation
Intervention  ICMJE Drug: Nivolumab
Treatment
Other Name: Opdivo
Study Arms  ICMJE Experimental: Nivolumab
Nivolumab 240 mg IV over 60 minutes every 14 days.
Intervention: Drug: Nivolumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 16, 2018)
300
Original Estimated Enrollment  ICMJE
 (submitted: January 4, 2017)
250
Estimated Study Completion Date  ICMJE December 2023
Estimated Primary Completion Date January 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patient information sheet and written informed consent form signed.
  2. Histologically confirmed diagnosis of a pathology corresponding to one of the following selected cancer types:

    • Non-clear cell renal-cell carcinomas: papillary renal cell carcinoma (pRCC, type I, type II and non-classified pRCC), chromophobe RCC (ChRCC), renal medullary carcinoma (RMC), collecting duct/Bellini duct carcinoma (CDC), microphthalmia-associated transcription (MiT) family translocation renal cell carcinoma (tRCC), renal cell carcinoma with a prominent sarcomatoid component (sarcRCC).
    • Rare head and neck cancers: principal and accessory salivary gland tumours, facial tissue tumours.
    • Rare skin cancers: adnexal carcinomas, basal cell carcinoma resistant to vismodegib.
    • Non-colorectal cancers with microsatellite instability determined locally by immunohistochemistry or polymerase chain-reaction (PCR)
    • Squamous cell carcinoma of penis.
    • Any non MSI-high cancer with POLE exonucleasic domain mutation (somatic or germline) in hotspots (codons 286, 411, 424 and 459) or other germline or somatic variants with high probability of pathogenesis according to in silico assessment by the INCa ad hoc biology group.
  3. Metastatic disease or unresectable locally advanced malignancy that is resistant or refractory to standard therapy or for which standard therapy does not exist or is not considered appropriate by the Investigator.
  4. Aged ≥ 18 years old.
  5. Measurable disease according to RECIST v1.1 guidelines for solid tumours.
  6. Able to provide a formalin fixed/paraffin embedded (FFPE) biopsy sample of a metastatic site or primitive tumour tissue.

    Note: Patients for whom suitable archived biopsy material is not available must be willing to undergo a biopsy of a tumour lesion prior to study entry, unless this is medically contraindicated (e.g. site inaccessible or patient safety concerns).

  7. Patients must have a mandatory treatment-free interval of at least 21 days following previous systemic anti-cancer treatments.
  8. Patients who have received previous systemic anticancer treatment and/or radiotherapy should have recovered from any treatment related toxicity, to a level of ≤ grade 1 (according to NCI-CTCAE criteria, v 4.0) with the exception of Grade 2 alopecia.
  9. Adequate hematologic function (absolute neutrophil count (ANC) ≥1.0 x10⁹/L, platelets ≥100 x10⁹/L, haemoglobin (Hb) ≥9 g/L) measured within 14 days of treatment initiation.
  10. Adequate renal function (creatinine clearance ≥50 mL/ using the glomerular filtration rate (MDRD) or CKI EPI method) measured within 14 days of treatment initiation.
  11. Adequate hepatic function (serum bilirubin ≤1.5 x the reference upper limit of normal (ULN) unless due to Gilbert's syndrome; aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) ≤2.5 xULN) measured within 14 days of treatment initiation. For patients with documented liver metastasis ASAT/ALAT ≤5x ULN is acceptable.
  12. Strictly normal blood levels of calcium and magnesium, measured within 14 days of treatment initiation.
  13. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤1.
  14. Estimated life expectancy ≥90 days.
  15. Patients who are sexually active must agree to use a medically accepted method of contraception (e.g. implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner, for participating women; condoms for participating men) or practice complete abstinence, beginning 14 days before the first administration of investigational product (IP), while on treatment and for at least 5 months after the last administration of IP for female patients, and 7 months after the last administration of IP for male patients.
  16. Women of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to the first administration of IP. If urine test results are positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  17. Women who are breastfeeding should discontinue nursing prior to the first administration of IP and for at least 90 days after the last administration of IP.
  18. Patients must be affiliated to a Social Security System or equivalent.

Exclusion Criteria:

  1. Prior treatment with an anti-PD1 or anti-PD-L1 antibody
  2. Eligible, and willing, to participate in a clinical trial of an alternative anticancer therapy targeting their disease which is open to accrual in France.
  3. Concurrent steroid medication at a dose greater than prednisone 10 mg/day or equivalent.
  4. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  5. History of (non-infectious) pneumonitis that required steroids, or current pneumonitis.
  6. History of severe hypersensitivity reaction to any monoclonal antibody therapy
  7. Radiotherapy (except for brain and extremities) within 21 days prior to the first administration of IP.
  8. Treatment with other investigational drugs or participation in another clinical trial within 21 days prior to the first administration of IP or concomitantly with the trial.
  9. Has known symptomatic central nervous system (CNS) metastases. Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment.
  10. Has known carcinomatous meningitis or a history of leptomeningeal disease.
  11. Serum creatinine >1.5 x ULN or glomerular filtration rate (GFR) <50 ml/min.
  12. Other malignancies within the past 5 years other than basal cell skin cancer or carcinoma in situ of the cervix.
  13. Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy.
  14. Active or chronic hepatitis B, hepatitis C and/or human immunodeficiency virus (HIV) infection (HIV 1/2 antibodies), or a known history of active Tuberculosis bacillus.
  15. Has received a live vaccine within 30 days of planned start of study treatment. Note: Seasonal influenza vaccines for injection are generally inactivated vaccines and are allowed; however intranasal influenza vaccines (e.g. Flu-Mist®) are live attenuated vaccines, and are not allowed.
  16. Active alcohol or drug abuse.
  17. Psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule.
  18. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Clotilde Simon +(33)1 73 79 79 11 c-simon@unicancer.fr
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03012581
Other Study ID Numbers  ICMJE UC-0105/1611
2016-002257-37 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party UNICANCER
Study Sponsor  ICMJE UNICANCER
Collaborators  ICMJE
  • National Cancer Institute, France
  • Ligue contre le cancer, France
  • Bristol-Myers Squibb
Investigators  ICMJE
Principal Investigator: Aurélien Marabelle, MD Gustave Roussy Cancer Campus
PRS Account UNICANCER
Verification Date October 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP